Obseva (NASDAQ:OBSV) Given a $38.00 Price Target at Wedbush

Wedbush set a $38.00 price objective on Obseva (NASDAQ:OBSV) in a report published on Monday morning, TipRanks reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also issued reports on OBSV. Zacks Investment Research raised York Water from a sell rating to a hold rating in a research note on Saturday, June 1st. ValuEngine lowered Valero Energy from a hold rating to a sell rating in a research note on Wednesday, May 8th. Finally, HC Wainwright reaffirmed a buy rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $28.83.

Shares of OBSV traded down $0.03 on Monday, reaching $10.63. The stock had a trading volume of 16,833 shares, compared to its average volume of 46,576. The stock has a market cap of $482.06 million, a price-to-earnings ratio of -5.57 and a beta of 0.94. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 6.73. The company’s 50-day moving average is $11.51. Obseva has a twelve month low of $9.73 and a twelve month high of $19.40.

Obseva (NASDAQ:OBSV) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.09). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. As a group, equities analysts anticipate that Obseva will post -2.32 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Fosun International Ltd purchased a new position in shares of Obseva during the 1st quarter worth $2,494,000. Polar Capital LLP lifted its stake in shares of Obseva by 16.7% during the 4th quarter. Polar Capital LLP now owns 175,000 shares of the company’s stock worth $2,216,000 after purchasing an additional 25,000 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Obseva by 274.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock worth $893,000 after purchasing an additional 51,733 shares during the period. Wedbush Securities Inc. lifted its stake in shares of Obseva by 86.1% during the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after purchasing an additional 17,950 shares during the period. Finally, United Services Automobile Association lifted its stake in shares of Obseva by 132.3% during the 4th quarter. United Services Automobile Association now owns 26,480 shares of the company’s stock worth $335,000 after purchasing an additional 15,080 shares during the period. 63.58% of the stock is currently owned by hedge funds and other institutional investors.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: How Do Mutual Funds Work?

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.